Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
5.35
+0.12 (2.29%)
Mar 3, 2026, 10:09 AM EST - Market open

Larimar Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
581247200179191329
Market Cap Growth
178.44%23.61%11.79%-6.49%-41.88%-
Enterprise Value
3974911060119233
Last Close Price
5.233.874.554.1310.7921.41
PB Ratio
3.221.442.441.612.973.67
P/TBV Ratio
4.081.442.441.612.973.67
Debt / Equity Ratio
0.030.030.070.050.090.07
Net Debt / Equity Ratio
-1.23-1.04-0.99-1.02-0.99-0.96
Net Debt / EBITDA Ratio
1.231.971.963.121.282.02
Net Debt / FCF Ratio
1.772.502.424.091.512.04
Quick Ratio
3.917.589.1611.067.9510.31
Current Ratio
4.068.029.4911.288.1610.89
Return on Equity (ROE)
-78.24%-63.59%-38.36%-40.33%-65.72%-95.47%
Return on Assets (ROA)
-42.99%-38.36%-23.48%-22.26%-34.40%-48.69%
Return on Capital Employed (ROCE)
-98.30%-51.70%-48.30%-31.60%-72.30%-44.70%
Earnings Yield
-23.24%-32.64%-18.50%-19.78%-26.50%-12.92%
FCF Yield
-17.04%-28.86%-16.83%-15.48%-22.21%-12.85%
Buyback Yield / Dilution
-20.08%-39.53%-70.42%-50.09%-44.44%-95.09%
Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q